ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2019 financial results.
Leveraging on-table MR soft tissue imaging, MRIdian allows oncologists to visualize, adapt and target using diagnostic-quality anatomical detail that’s simply unavailable with conventional IGRT technologies.
Combining the latest innovations in precision radiation delivery, ground-breaking MR image guidance, and on-table adaptive therapy, MRIdian represents a new paradigm in radiation oncology.
ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2019 financial results.
ViewRay Announces Appointment of Dr. Gail Wilensky to its Board of Directors
ViewRay, Inc. (Nasdaq: VRAY) announced the appointment of Dr. Gail Wilensky to its Board of Directors, effective today.
Presentations Highlight MRIdian Clinical Experience with Real-Time On-Table Adaptive Radiotherapy at a Growing Number of Institutions Worldwide
A new kind of medical technology company—ViewRay® Inc. designs, manufactures and markets MRIdian, the world’s first MRI-Guided radiation therapy system to image and treat cancer patients simultaneously.
Contact Us Today To Learn More Contact
This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy